CC
SLNO

Centiva Capital’s Soleno Therapeutics SLNO Stock Holding History

Centiva Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,100
Closed -$2.1M – 1565
2025
Q3 		$2.1M Buy
+31,100
New +$2.31M 0.02% 373

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Centiva Capital's SLNO Position: Q1 2026 in Review

Centiva Capital reduced its Soleno Therapeutics (SLNO) stake by 15% in Q1 2026, selling an estimated $689K and leaving 101,234 shares worth $3.39M. The position accounts for 0.03% of the portfolio, ranked #330.

Centiva Capital first reported a position in SLNO in Q1 2025 and has held it in 4 quarters since. The position peaked at $5.5M in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Centiva Capital held 101,234 shares of Soleno Therapeutics worth $3.39M as of Q1 2026.
  • Centiva Capital sold 17,570 Soleno Therapeutics shares in Q1 2026, an estimated $689K.
  • Soleno Therapeutics made up 0.03% of Centiva Capital's portfolio in Q1 2026, its #330 holding.
  • Centiva Capital first reported a position in Soleno Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Centiva Capital's Soleno Therapeutics position peaked at $5.5M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.